McDermott Advises Acticor Biotech in EUR 60m+ Agreement with China Medical System Holding Limited®
PARIS – International law firm McDermott Will & Emery advised Acticor Biotech in signing an asset transfer and licensing agreement with CMS Medical Limited regarding the development and commercialization of Acticor’s flagship candidate-drug, ACT017. McDermott also advised on an investment agreement with CMS Medical Venture Investment Limited, a wholly owned subsidiary of China Medical System Holdings Limited®.
Acticor Biotech is a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism. Currently in clinical trials, ACT017 is an innovative biotechnological candidate-drug in the emergency treatment of the above.
The McDermott team advised on corporate aspects of the transaction and was led by Paris-based Transactions partner Emmanuelle Trombe, with support from associates Laetitia de Dinechin and Shurong Qu.
About McDermott’s Corporate & Transactional Practice
McDermott’s Corporate & Transactional Practice represents business interests around the world, from global corporations and industry-leading companies to privately funded and entrepreneurial driven enterprises, private equity sponsors and the financial institutions that support them. McDermott consistently ranks in the leading league tables, including Mergermarket, Thomson Reuters, Bloomberg and PitchBook, and is highly ranked across major legal directories in the United States and in Europe.
McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,000 lawyers, we have offices in Boston, Brussels, Chicago, Dallas, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, San Francisco, Seoul, Silicon Valley and Washington, DC. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.